SCHEDULE: Fairmount Funds Discloses 6.3% Stake in Enliven
Beneficial Ownership Report
Fairmount Funds Management LLC and related entities reported a 6.3% beneficial ownership stake in Enliven Therapeutics, Inc. common stock.
Summary
- Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Harwin, and Tomas Kiselak collectively reported beneficial ownership of 3,711,444 shares of Enliven Therapeutics, Inc. Common Stock.
- This ownership represents 6.3% of the Issuer's outstanding Common Stock.
- The percentage calculation is based on 58,959,717 shares of Common Stock outstanding as of June 16, 2025.
- Fairmount Funds Management LLC serves as the investment adviser for Fairmount Healthcare Fund II L.P. and holds sole voting and dispositive power over the reported securities.
- Peter Harwin and Tomas Kiselak are managing members of Fairmount Funds Management LLC and are deemed beneficial owners.
- This filing is Amendment No. 4 to the original Schedule 13G filed on April 27, 2023.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects.
Risks
- The reported securities were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11 of the Securities Exchange Act of 1934.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of a significant passive investment by an institutional fund in a publicly traded biotechnology or pharmaceutical company, common within the healthcare investment sector.
Stakeholder Impact
- Shareholders are informed of a significant passive ownership stake held by Fairmount Funds Management LLC and its affiliates, indicating continued institutional interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2023-04-27 | Original Schedule 13G filing date |
| 2024-02-14 | Amendment No. 1 filing date |
| 2024-11-14 | Amendment No. 2 filing date |
| 2025-02-14 | Amendment No. 3 filing date |
| 2025-06-16 | Date as of which the number of outstanding shares (58,959,717) was determined for percentage calculation |
| 2025-06-30 | Date of event which requires filing of this statement |
| 2025-08-14 | Current Schedule 13G Amendment No. 4 filing date |
Keywords
Enliven Therapeutics, Fairmount Funds Management, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Healthcare Fund
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.